Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Cantargia AB ( (SE:CANTA) ) has shared an update.
Cantargia AB announced that its anti-IL1RAP antibody, nadunolimab, has received Fast Track Designation from the US FDA for treating metastatic pancreatic ductal adenocarcinoma (PDAC) with high IL1RAP expression. This designation, following promising clinical data, will facilitate the drug’s development with more frequent FDA interactions and potential for accelerated approval. The recognition underscores the high unmet medical need in metastatic PDAC and strengthens Cantargia’s efforts to provide new treatment options for patients with limited alternatives.
More about Cantargia AB
Cantargia AB is a biotechnology company focused on developing antibody-based treatments for life-threatening diseases. The company has established a platform based on the protein IL1RAP, which is involved in various cancer forms and inflammatory diseases. Cantargia’s oncology program includes the antibody nadunolimab, primarily studied in combination with chemotherapy for pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer. Additionally, Cantargia is developing CAN10 for autoimmune/inflammatory diseases.
Average Trading Volume: 653,529
Current Market Cap: SEK289.4M
See more data about CANTA stock on TipRanks’ Stock Analysis page.